Drugs Made In America Acquisition II Corp. Unit
NASDAQ Global SelectTotal Valuation
Drugs Made In America Acquisition II Corp. Unit carries a market capitalization of 709.35M, placing it among publicly traded companies globally.
| Market Cap | 709.35M |
| Enterprise Value | N/A |
Share Statistics
Drugs Made In America Acquisition II Corp. Unit currently has 63.70M shares outstanding.
| Shares Outstanding | 63.70M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 1.30 |
| P/TBV Ratio | 1.30 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Financial Position
Drugs Made In America Acquisition II Corp. Unit maintains a current ratio of 0.34, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.34 |
| Quick Ratio | 0.27 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 8.43 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Drugs Made In America Acquisition II Corp. Unit's stock has gained approximately 2.51256% over the past 52 weeks. The 50-day moving average sits at 10.19, while the 200-day moving average is 10.11.
| Beta (5Y) | N/A |
| 52-Week Price Change | 2.51256% |
| 50-Day Moving Average | 10.19 |
| 200-Day Moving Average | 10.11 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -1.42M, while operating income came in at -1.42M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -1.42M |
| Pretax Income | 13.02M |
| Net Income | 13.02M |
| EBITDA | -1.42M |
| EBIT | -1.42M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Total book value stands at 495.96M, with working capital of -426,751.00 providing operational flexibility.
| Cash & Cash Equivalents | 174,974.00 |
| Total Debt | N/A |
| Net Debt | 275,026.00 |
| Equity (Book Value) | 495.96M |
| Book Value Per Share | 7.79 |
| Working Capital | -426,751.00 |
Cash Flow
Drugs Made In America Acquisition II Corp. Unit produced -1.28M in operating cash flow over the past twelve months.
| Operating Cash Flow | -1.28M |
| Capital Expenditures | N/A |
| Free Cash Flow | -1.28M |
| FCF Per Share | N/A |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -77.48 |
| FCF Yield | N/A |
Scores
Drugs Made In America Acquisition II Corp. Unit posts an Altman Z-Score of 21.34, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 21.34 |